Previous Close | 63.69 |
Open | 63.69 |
Bid | 63.55 x 0 |
Ask | 63.76 x 0 |
Day's Range | 63.69 - 63.69 |
52 Week Range | 57.38 - 80.14 |
Volume | |
Avg. Volume | 19 |
Market Cap | N/A |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | Aug 08, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Following this sale, the insider now owns 96,380 shares of Gilead Sciences Inc. Gilead Sciences Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. The company's portfolio includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions.
NORTHAMPTON, MA / ACCESSWIRE / July 1, 2024 / Jim Candler had a successful 40-year career in system operations before coming to Gilead three years ago to bring his tech expertise to the Human Resources team. "I was hired at 71 years old. What does ...